Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients

Julie Graff, Tomasz (Tom) Beer, Bian Liu, Guru Sonpavde, Emanuela Taioli

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction Previous studies have reported that higher C-reactive protein (CRP) levels are significantly associated with worse outcome in prostate cancer patients. The size of each individual study was not large enough to allow sufficient statistical power to draw conclusions. We conducted a pooled analysis of individual data of published studies to evaluate the association between increased CRP level and risk of death in prostate cancer, and to find the best CRP cutoff that could predict mortality. Materials and Methods Original research studies on prostate cancer survival and CRP levels were identified (n = 6). Corresponding authors were contacted and invited to share individual data. Two data sets were received (235 patients). The combined hazard ratio (HR) was calculated and adjusted for age, prostate-specific antigen, hemoglobin, and alkaline phosphatase. The best cutoff of CRP was explored using X-title software version 3.6.1. Results High CRP level was statistically significantly associated with mortality (meta-HR, 1.83 [95% confidence interval (CI), 1.51-2.21]), without evidence of heterogeneity among studies. At pooled analysis, adjusted pooled HR for CRP <5 versus ≤ 5 mg/L was 1.44 (95% CI, 1.02-20.4). The best CRP cutoff was 12 mg/L: the adjusted HRpooled for CRP <12 versus ≥ 12 mg/L was 1.53 (95% CI, 1.01-2.32). Conclusion Increased CRP levels are associated with overall survival in prostate cancer patients. Because CRP is an affordable and readily available assay, it might hold promise in improving prognostication and potentially to predict the activity of specific therapeutic agents.

Original languageEnglish (US)
Pages (from-to)e217-e221
JournalClinical Genitourinary Cancer
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2015

Fingerprint

C-Reactive Protein
Prostatic Neoplasms
Mortality
Confidence Intervals
Survival
Prostate-Specific Antigen
Alkaline Phosphatase
Hemoglobins
Software

Keywords

  • Epidemiological methods
  • Outcome
  • Prognostic markers
  • Systemic inflammation
  • Urological cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. / Graff, Julie; Beer, Tomasz (Tom); Liu, Bian; Sonpavde, Guru; Taioli, Emanuela.

In: Clinical Genitourinary Cancer, Vol. 13, No. 4, 01.08.2015, p. e217-e221.

Research output: Contribution to journalArticle

@article{3206c58363e746329828a44d2b6c819c,
title = "Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients",
abstract = "Introduction Previous studies have reported that higher C-reactive protein (CRP) levels are significantly associated with worse outcome in prostate cancer patients. The size of each individual study was not large enough to allow sufficient statistical power to draw conclusions. We conducted a pooled analysis of individual data of published studies to evaluate the association between increased CRP level and risk of death in prostate cancer, and to find the best CRP cutoff that could predict mortality. Materials and Methods Original research studies on prostate cancer survival and CRP levels were identified (n = 6). Corresponding authors were contacted and invited to share individual data. Two data sets were received (235 patients). The combined hazard ratio (HR) was calculated and adjusted for age, prostate-specific antigen, hemoglobin, and alkaline phosphatase. The best cutoff of CRP was explored using X-title software version 3.6.1. Results High CRP level was statistically significantly associated with mortality (meta-HR, 1.83 [95{\%} confidence interval (CI), 1.51-2.21]), without evidence of heterogeneity among studies. At pooled analysis, adjusted pooled HR for CRP <5 versus ≤ 5 mg/L was 1.44 (95{\%} CI, 1.02-20.4). The best CRP cutoff was 12 mg/L: the adjusted HRpooled for CRP <12 versus ≥ 12 mg/L was 1.53 (95{\%} CI, 1.01-2.32). Conclusion Increased CRP levels are associated with overall survival in prostate cancer patients. Because CRP is an affordable and readily available assay, it might hold promise in improving prognostication and potentially to predict the activity of specific therapeutic agents.",
keywords = "Epidemiological methods, Outcome, Prognostic markers, Systemic inflammation, Urological cancer",
author = "Julie Graff and Beer, {Tomasz (Tom)} and Bian Liu and Guru Sonpavde and Emanuela Taioli",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.clgc.2015.01.011",
language = "English (US)",
volume = "13",
pages = "e217--e221",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients

AU - Graff, Julie

AU - Beer, Tomasz (Tom)

AU - Liu, Bian

AU - Sonpavde, Guru

AU - Taioli, Emanuela

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Introduction Previous studies have reported that higher C-reactive protein (CRP) levels are significantly associated with worse outcome in prostate cancer patients. The size of each individual study was not large enough to allow sufficient statistical power to draw conclusions. We conducted a pooled analysis of individual data of published studies to evaluate the association between increased CRP level and risk of death in prostate cancer, and to find the best CRP cutoff that could predict mortality. Materials and Methods Original research studies on prostate cancer survival and CRP levels were identified (n = 6). Corresponding authors were contacted and invited to share individual data. Two data sets were received (235 patients). The combined hazard ratio (HR) was calculated and adjusted for age, prostate-specific antigen, hemoglobin, and alkaline phosphatase. The best cutoff of CRP was explored using X-title software version 3.6.1. Results High CRP level was statistically significantly associated with mortality (meta-HR, 1.83 [95% confidence interval (CI), 1.51-2.21]), without evidence of heterogeneity among studies. At pooled analysis, adjusted pooled HR for CRP <5 versus ≤ 5 mg/L was 1.44 (95% CI, 1.02-20.4). The best CRP cutoff was 12 mg/L: the adjusted HRpooled for CRP <12 versus ≥ 12 mg/L was 1.53 (95% CI, 1.01-2.32). Conclusion Increased CRP levels are associated with overall survival in prostate cancer patients. Because CRP is an affordable and readily available assay, it might hold promise in improving prognostication and potentially to predict the activity of specific therapeutic agents.

AB - Introduction Previous studies have reported that higher C-reactive protein (CRP) levels are significantly associated with worse outcome in prostate cancer patients. The size of each individual study was not large enough to allow sufficient statistical power to draw conclusions. We conducted a pooled analysis of individual data of published studies to evaluate the association between increased CRP level and risk of death in prostate cancer, and to find the best CRP cutoff that could predict mortality. Materials and Methods Original research studies on prostate cancer survival and CRP levels were identified (n = 6). Corresponding authors were contacted and invited to share individual data. Two data sets were received (235 patients). The combined hazard ratio (HR) was calculated and adjusted for age, prostate-specific antigen, hemoglobin, and alkaline phosphatase. The best cutoff of CRP was explored using X-title software version 3.6.1. Results High CRP level was statistically significantly associated with mortality (meta-HR, 1.83 [95% confidence interval (CI), 1.51-2.21]), without evidence of heterogeneity among studies. At pooled analysis, adjusted pooled HR for CRP <5 versus ≤ 5 mg/L was 1.44 (95% CI, 1.02-20.4). The best CRP cutoff was 12 mg/L: the adjusted HRpooled for CRP <12 versus ≥ 12 mg/L was 1.53 (95% CI, 1.01-2.32). Conclusion Increased CRP levels are associated with overall survival in prostate cancer patients. Because CRP is an affordable and readily available assay, it might hold promise in improving prognostication and potentially to predict the activity of specific therapeutic agents.

KW - Epidemiological methods

KW - Outcome

KW - Prognostic markers

KW - Systemic inflammation

KW - Urological cancer

UR - http://www.scopus.com/inward/record.url?scp=84930900254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930900254&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2015.01.011

DO - 10.1016/j.clgc.2015.01.011

M3 - Article

C2 - 25735198

AN - SCOPUS:84930900254

VL - 13

SP - e217-e221

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -